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PROGRESSIVE SuPRANUCLEAR PALSY

DESCRIPTION
Progressive supranuclear palsy (PSP) is one of the
most common parkinsonism-plus syndromes. Acknowledging the seminal contributions of the three
physicians who first described the condition (Steele,
Richardson, & Olszweski, 1964), PSP is also referred
to as Steele-Richardson-Olszweski syndrome. PSP
is a rapidly progressive degenerative disease. The
characteristic syndrome consists of supranuclear
ophthalmoplegia, pseudobulbar palsy, and axial

dystonia, although it may take over a year for these
features to develop fully (Ropper & Brown, 2005).
Early prominent features include postural
instability, falls, executive dysfunction, and slowed
information processing. The hallmark symptom is a
vertical gaze palsy that is often downward but can
sometimes occur only upward. Typical age of onset
is in the 60s (range 45-75 years) with a median survival time of approximately 6 years from the initial
onset of symptoms (Litvan, Agid, et al., 1996; Litvan,
Mangone, et al., 1996). There are conflicting reports
whether males or females are more likely to develop
PSP (Bower, Maraganore, McDonnell, & Roca, 1997;
Golbe, 1996). Overall prevalence is estimated between
1.4 and 6.4 per 100,000 (Golbe, Davis, Schoenberg, &
Duvoisin, 1988; Schrag, Ben-Shlomo, & Quinn, 1999).

NEUROPATHOLOGY /PATHOPHYSIOLOGY
The pathophysiology of PSP involves severe neuronal
degeneration of subcortical structures and minimal
cortical lesions. Lesion sites are somewhat variable
and typically occur between the upper brainstem
and basal ganglia. Broadly, there is evidence of neuronal loss in the striatum and substantia nigra, and
degeneration of structures in the basal ganglia,
upper brainstem, and cerebellum (Agid, Ruberg,
DuBois, & Pillon, 1987). Lesions may compromise
the nigrostriatal pathway, basal forebrain, pedunculopontine nucleus, subnucleus compactus, mesencephalopontine tegmental nuclei, and locus ceruleus
(Grafman, Litvan, & Stark, 1995). Dopamine levels
drop drastically during the course of the illness
leading to parkinsonian-type symptoms.
Degeneration impacts ascending pathways from
subcortical structures to the prefrontal cortex. Grafman et al. (1995) hypothesized that pathology in the
dorsolateral frontal, lateral-orbitofrontal, and anterior
cingulate circuits contributes to specific cognitive
dysfunctions (executive functioning, social-cognitive,
and attention).
Although frontal lobe pathology is not prominent, multiple positron emission tomography (PET)
studies have revealed frontal hypometabolism
(Bhatt, Snow, Martin, Peppard, & Caine, 1991; Blin
et al., 1990; Blin et al., 1992), and some imaging studies
have reported significant frontal cortical atrophy
(Cordato, Halliday, Harding, Hely, & Morris, 2000;
Cordato et al., 2002; Groschel et al., 2004). MRI studies
have found atrophy of midbrain structures most pronounced in the superior colliculi and pons (Masucci,
Borts, Smimiotopoulos, Kurtzke, & Schellinger, 1985;
Schonfeld, Globe, Sage, Safer, & Duvoisin, 1987).
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NEUROPSYCHOLOGICAL/ CLINICAL
PRESENTATION
Consistent with subcortical dysfunction, common
manifestations of PSP reflect executive dysfunction,
including cognitive slowing, impaired set-shifting,
and decreased verbal fluency (Grafman et al., 1995;
Jacobs, Levy, & Marder, 2003). It is generally believed
that these deficits are related to frontal deafferentation
secondary to subclinical lesions, although some
researchers have hypothesized a more direct relationship between frontal lobe pathology and behavioral
deficits (Cordato et al., 2002). Immediate and delayed
recall of information can vary from normal to
impaired, whereas recognition memory is improved
or intact (Jacobs et al., 2003). Primary language
abilities are typically preserved, though word-finding
problems may develop years following formal
diagnosis (Lezak, Howieson, & Loring, 2004). Not
surprisingly given ocular involvement, visuospatial
skills are often impaired. Visual attention impairment
is typically related to duration of PSP (Kertzman,
Robinson, & Litvan, 1990).
The course of physical symptoms consists of
postural instability and falls several years prior to
formal diagnosis. The hallmark physical symptom
of PSP is a vertical gaze palsy that typically occurs
relatively late in the disease process. Compensation
for visual limitations can frequently lead to falls.
Bradykinesia, rigidity, impaired control of mouth/
neck are also relatively common later in the course.
It is notable that the development of core symptoms
may present late, or never develop, during the
course of the disease (Litvan et al., 2003). For example,
histological confirmed cases of PSP have been
reported without ophthalmoplegia (Santacruz, Uttl,
Litvan, & Grafman, 1998). Respiratory arrest may
occur due to a degenerative process involving the
brainstem respiratory centers, or be secondary to
pneumonia. Unlike Parkinson's disease, patients
with PSP tend to have more of an erect rather than a
stooped posture and lack tremor (Rapper & Brown,
2005).
Consistent with executive dysfunction, two of
the most common behavioral manifestations of PSP
are apathy and disinhibition. One study administered
the Neuropsychiatric Inventory to 22 patients with PSP
and found apathy to be the most prevalent
neuropsychiatric feature, present in 91% of patients
(Litvan, Mega, Cummings, & Fairbanks, 1996). Disinhibition was exhibited by one-third of patients,
followed by dysphoria (18%) and anxiety (18%).
Impaired metacognitive awareness has also been
observed and is attributed to the disruption of

frontostriatal feedback loops (O'Keeffe et al., 2007).
Obsessive behaviors, euphoria, and depressive
symptoms are also possible (Destee et al., 1990).
Sleep abnormalities are prevalent as well and are
most often characterized by shortened total sleep
time, frequent awakenings, and decreased REM sleep
(Cummings, 2003).

DIAGNOSIS
Although multiple diagnostic criteria have been
proposed (e.g., Collins, Ahlskog, Parisi, & Maraganore, 1995; Tolosa, Valldeoriola, & Marti, 1994),
those set forth by Litvan et al. (1996) are the most
frequently cited in the literature and form the basis
for the National Institute of Neurological Disorders
and Stroke and Society for Progressive Supranuclear
Palsy (NINDS-SPSP; Litvan et al., 2003) clinical criteria. Diagnosis of "possible PSP" requires either
vertical supranuclear palsy or both slowing of vertical
saccades and postural instability with falls during the
1st year of disease onset. "Probable" diagnosis of PSP
requires vertical supranuclear palsy and prominent
postural instability with falls within the 1st year of
disease onset. Diagnosis of possible or probable PSP
requires symptom onset at or after age 40, and it is
necessary that there be a gradual progression of symptoms. "Definite" diagnosis of possible or probable PSP
requires histopathologic confirmation at autopsy.
NINDS-SPSP clinical criteria provide a number of
supportive criteria to assist in differential diagnosis.
Supportive motor features include symmetric akinesia
or rigidity (proximal greater than distal) and neck dystonia. An early onset of two or more of the following
cognitive symptoms is also supportive of PSP diagnosis: impaired abstraction, decreased verbal fluency,
"utilization or imitation behavior," "frontal release"
signs, and apathy. In addition, PSP may be considered
if motor symptoms do not respond, or minimally
respond, to levodopa therapy and if there are early
symptoms of dysphagia or dysarthria.
PSP is often misdiagnosed early in the course of
the disease as Parkinson's disease or confused with
other parkinsonian disorders. Severity and pattern
of executive deficits characterized by slowed information processing, impaired accuracy in carrying out
plans, and difficulty in set shifting tends to differentiate PSP patients from others with basal ganglia lesions
(Robbins et al., 1994). The combination of postural
instability leading to falls early in the course of the
disease and vertical gaze palsy are also key symptoms
in differentiating PSP from other disorders with
parkinsonism and dementia.

616. PROGRESSIVE SUPRANUCLEAR PALSY

Neuroimaging techniques can be useful in
differential diagnosis. Diffusion-weighted imaging
has shown promise in differentiating PSP from Parkinson's disease early in disease onset based on
increased regional apparent diffusion coefficients in
the putamen, globus pallidus, and caudate nucleus
(Seppi et al., 2003). An additional reliable manner to
differentiate PSP from Parkinson's disease is significantly lower anteroposterior diameter of the midbrain
on axial T2-weighted magnetic resonance images
(Warmuth-Metz, Naumann, Csoti, & Solymosi, 2001).
Differential diagnosis between PSP and corticobasal degenerative syndrome (CBDS) is challenging.
These conditions have numerous factors in common
including similar neuropsychological profiles (Pillon
et al., 1995), pathological features (Feany, Mattiace, &
Dickson, 1996), and the finding that both conditions
are considered to be predominantly 4-repeat tauopathies (Kertesz & Munoz, 2004). Further complicating
the differential diagnosis, individuals with CBDS may
exhibit vertical gaze palsy, falls, and symmetrical
extrapyramidal syndrome (Litvan, Goetz, & Lang,
2000). One possible distinguishing feature between
these syndromes is greater atrophy of the midbrain,
pons, thalamus, and striatum in PSP relative to CBDS
(Boxer et al., 2006).
TREATMENT

Unfortunately, PSP is a treatment-resistant and degenerative condition. Although dopaminergic agents
can improve the parkinsonian features, they can
also induce adverse side effects, such as orthostatic
hypotension, hallucinations/ delusions, and gastrointestinal complaints (Kompoliti, Goetz, Litvan,
Jellinger, & Vemy, 1998). It is recommended that
anticholinergic agents be avoided (Cummings,
2003). There is no significant improvement with levadopa therapy.
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PsEuooTUMOR CEREBRI

DESCRIPTION

Pseudotumor cerebri represents a syndrome that is
characterized by persisting headache and papilledema (unilateral or bilateral) in the absence of focal
neurologic signs, abnormal CSF composition, and
enlarged ventricles or an intracranial mass. The presentation is associated with increased intracranial
hypertension, most commonly idiopathic in nature.
Pseudotumor cerebri is most frequently observed
in overweight young women with a relative

